Last updated: 20 June 2019 at 2:33am EST

Lupe M Rivera Net Worth




The estimated Net Worth of Lupe M Rivera is at least 523 千$ dollars as of 15 August 2011. Lupe Rivera owns over 3,203 units of Exelixis Inc stock worth over 511,802$ and over the last 19 years Lupe sold EXEL stock worth over 11,021$.

Lupe Rivera EXEL stock SEC Form 4 insiders trading

Lupe has made over 8 trades of the Exelixis Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently Lupe exercised 3,203 units of EXEL stock worth 85,296$ on 15 August 2011.

The largest trade Lupe's ever made was exercising 75,000 units of Exelixis Inc stock on 14 December 2010 worth over 422,250$. On average, Lupe trades about 8,139 units every 73 days since 2005. As of 15 August 2011 Lupe still owns at least 19,219 units of Exelixis Inc stock.

You can see the complete history of Lupe Rivera stock trades at the bottom of the page.



What's Lupe Rivera's mailing address?

Lupe's mailing address filed with the SEC is C/O EXELIXIS, INC., 170 HARBOR WAY, PO BOX 511, SOUTH SAN FRANCISCO, X1, 94083-0511.

Insiders trading at Exelixis Inc

Over the last 22 years, insiders at Exelixis Inc have traded over 82,392,913$ worth of Exelixis Inc stock and bought 1,847,609 units worth 19,175,184$ . The most active insiders traders include Jean Francois FormelaMichael MorrisseyStelios Papadopoulos. On average, Exelixis Inc executives and independent directors trade stock every 12 days with the average trade being worth of 898,709$. The most recent stock trade was executed by Jeffrey Hessekiel on 26 August 2024, trading 20,000 units of EXEL stock currently worth 488,200$.



What does Exelixis Inc do?

exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.



Complete history of Lupe Rivera stock trades at Exelixis Inc

インサイダー
取引
取引
合計金額
Lupe M Rivera
副総裁、HUMAN RESOURCES
オプション行使 22,837$
15 Aug 2011
Lupe M Rivera
副総裁、HUMAN RESOURCES
オプション行使 35,041$
15 May 2011
Lupe M Rivera
副総裁、HUMAN RESOURCES
オプション行使 128,643$
15 Feb 2011
Lupe M Rivera
副総裁、HUMAN RESOURCES
オプション行使 160,377$
17 Dec 2010
Lupe M Rivera
副総裁、HUMAN RESOURCES
オプション行使 422,250$
14 Dec 2010
Lupe M Rivera
副総裁、HUMAN RESOURCES
オプション行使 47,250$
24 Dec 2009
Lupe M Rivera
副総裁、HUMAN RESOURCES
オプション行使 15,750$
16 Dec 2009
Lupe M Rivera
副総裁、HUMAN RESOURCES
販売 11,021$
17 Mar 2008


Exelixis Inc executives and stock owners

Exelixis Inc executives and other stock owners filed with the SEC include: